ArticleWorld journal of surgical oncology2026
Identification of immune and ferroptosis-related gene cysteine dioxygenase type 1 (CDO1) as a prognostic biomarker in colorectal cancer, relating to immunotherapy response distinction.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CDO1 as a prognostic biomarker and therapeutic target in gastric cancer: Mechanistic insights into the PI3K/AKT-THBS1 axis and epigenetic reactivation by decitabine.Clinical and translational medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundColorectal cancer (CRC) is the third most common cause of cancer deaths worldwide, and has a poor prognosis in advanced stages. Whereas there are limited effective biomarkers of CRC. Herein, we aimed to explore the potential prognostic value of immune and ferroptosis-related genes (IFRGs).
methodsCRC-related data were extracted from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Kaplan-Meier, receiver operating characteristic (ROC), and multivariate Cox regression analyses were used to test the prognostic value of IFRGs. The immune cell infiltration and immunotherapy response predictive analyses were also conducted. The level of cysteine dioxygenase type 1 (CDO1) mRNA and protein expression in CRC and normal tissues was examined using quantitative reverse transcription polymerase chain reaction (qRT-PCR) and Western blotting analysis, respectively.
resultsThirty-eight IFRGs were obtained through differentially expressed gene analysis and cross-analysis. Of them, CDO1 mRNA and protein expression levels were significantly reduced in CRC tissues compared to normal tissues. CDO1 remained as an independent prognostic biomarker after multivariate Cox regression. Additionally, CDO1 hypermethylation was associated with poorer prognosis of CRC patients. CRC patients with differential CDO1 expression or methylation status both showed significantly distinct immune cell infiltration and immunotherapy responses.
conclusionsOur study revealed CDO1 as an IFRG with a prognostic role in CRC. It may provide a rationale for developing novel treatment strategies, such as demethylating agents or combination immunotherapy protocols, for CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.